Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in non-small cell lung cancer
- Trial result
Non-small cell lung cancer
Taletrectinib Hits 89% ORR and 45.6-Month PFS in TKI-Naïve ROS1-Positive NSCLC
Taletrectinib, a next-generation ROS1/ALK tyrosine-kinase inhibitor designed to cover the G2032R resistance mutation and penetrate the CNS, was evaluated in the pooled Phase II TRUST-I/II program…
NCT04395677 - Trial result
Non-small cell lung cancer
Lorlatinib Depth of Response Tracks with 75% 5-Year PFS in First-Line ALK-Positive NSCLC
In the phase 3 CROWN trial (lorlatinib, a ALK inhibitor, n = 149 vs. crizotinib, an ALK and cMET TKI inhibitor, n = 147), 95% of lorlatinib-treated, treatment-naïve ALK-positive NSCLC patients were evaluable for…
- Trial result
Non-small cell lung cancer
Amivantamab + Carbo-Paclitaxel Halves Risk of Progression After Osimertinib—Regardless of EGFR or MET Resistance Mechanism
In the phase 3 MARIPOSA-2 trial (NCT04988295) of EGFR-mutant (Ex19del/L858R), which accounts for about 32% of all NSCLC cases%20in%20Europe.), advanced NSCLC patients that had progressed on osimertinib, 131 patients…
NCT04988295 - Trial result
Non-small cell lung cancer
Adagrasib + Pembrolizumab Posts 44% ORR and 26-Month DoR as Chemo-Free First-Line Option for KRAS-G12C NSCLC
In the Phase 2 KRYSTAL-7 study (NCT04613596), 149 untreated metastatic KRAS-G12C NSCLC patients received adagrasib (KRAS G12C inhibitor) 400 mg BID plus pembrolizumab (PD-1 checkpoint inhibitor) Q3W. About 13% of…
NCT04613596 - Trial result
Non-small cell lung cancer
Olomorasib + Pembrolizumab Delivers 70% ORR and 80% 6-mo PFS in Front-Line KRAS-G12C NSCLC
Olomorasib (LY3537982), a next-generation covalent KRAS-G12C inhibitor, was combined with pembrolizumab (PD-1 checkpoint inhibitor) in the Phase 1/2 LOXO-RAS-20001 trial (NCT04956640). 43 previously untreated…
NCT04956640 - Trial result
Non-small cell lung cancer
Teliso-V ctDNA Study Finds 100% ORR in KRAS-G12C and Better Survival When Baseline ctDNA Is Low
In the LUMINOSITY stage-2 analysis, 83 previously treated, EGFR-wild-type, c-Met-overexpressing NSCLC patients received telisotuzumab vedotin, an ADC targeting c-MET, 1.9 mg/kg Q2W and had serial 521-gene ctDNA…
- Trial result
Non-small cell lung cancer
Relatlimab (LAG-3) + Nivolumab/Platinum Chemo Expands LAG-3⁺ Memory T Cells and Cuts Risk of Progression 45% in PD-L1 ≥1% Non-Sq NSCLC
In the Phase 2 RELATIVITY-104 study (NCT04623775), 1L metastatic NSCLC patients received nivolumab (PD-1 checkpoint inhibitor) + platinum-doublet chemotherapy with or without high-dose relatlimab (anti-LAG-3…
NCT04623775 - New trial
Non-small cell lung cancer
Phase II alectinib ALK kinase inhibitor trial in resectable NSCLC
This multicenter study sponsored by Hoffmann-La Roche evaluates the safety and efficacy of adjuvant and perioperative alectinib combined with platinum-based chemotherapy in patients with resectable Stage II–IIIB…
NCT06624059 - New trial
Non-small cell lung cancer
Phase 1b/2 trial: cemiplimab (PD-1 inhibitor) with investigational anti-TIM3, anti-CD73, and anti-NKG2A antibodies
This multicenter, open-label study by Servier Bio-Innovation LLC evaluates cemiplimab combined with novel agents in adult patients with untreated advanced/metastatic NSCLC with high PD-L1 expression. The trial…
NCT06162572 - New trial
Non-small cell lung cancer
Phase Ib/II Trial of AB248 Plus Rilvegostomig, a Tigit and PD-1 Bispecific mAb
This open-label, multicenter platform study evaluates safety and efficacy of AB248 with rilvegostomig, alone or with standard chemotherapy, in patients with metastatic non-small cell lung cancer (PD-L1 ≥1%). It aims…
NCT06996782 - New trial
Non-small cell lung cancer
Phase 2 trial: Patritumab Deruxtecan, a HER3-directed antibody-drug conjugate with Pembrolizumab.
This umbrella study investigates adding investigational agents to pembrolizumab with or without platinum-based chemotherapy in treatment-naïve patients with stage IV NSCLC. Evaluating safety and efficacy in…
NCT06731907 - New trial
Non-small cell lung cancer
Phase II/III trial of cemiplimab PD-1 inhibitor in advanced NSCLC.
This randomized study compares adding cemiplimab to docetaxel and ramucirumab versus standard therapy in patients with stage IV or recurrent non-small cell lung cancer after platinum-based chemotherapy and…
NCT06616584 - New trial
Non-small cell lung cancer
Phase 2 PORT modulator "PORTight": a ctDNA-guided adjuvant radiation enhancer for NSCLC.
This Phase 2 single‐arm trial by Rutgers assesses whether postoperative ctDNA positivity can effectively guide adjuvant treatment decisions—including radiation therapy, chemotherapy, immunotherapy, or targeted…
NCT06979661 - New trial
Non-small cell lung cancer
Phase 3 RMC-6236 pan-KRAS inhibitor in RAS-mutated NSCLC
This Phase 3 trial compares safety and efficacy of RMC-6236 versus docetaxel in patients with advanced non‐small cell lung cancer harboring RAS mutations after prior treatment. Sponsored by Revolution Medicines,…
NCT06881784 - Trial result
Non-small cell lung cancer
Oral HER2-selective TKI Zongertinib Logs 71% ORR and 12-mo PFS in Pretreated HER2-Mutant NSCLC
Zongertinib (BI 1810631) is an irreversible HER2 tyrosine-kinase inhibitor that spares EGFR. In the phase Ia/Ib Beamion LUNG-1 study (AACR CT050; NCT04886804), 75 previously treated advanced NSCLC patients with HER2…
NCT04886804 - Trial result
Non-small cell lung cancer
Zoldonrasib (RMC-9805) Hits 61% ORR in KRAS-G12D–Mutant NSCLC Dose-Expansion presented at AACR
Zoldonrasib is an oral, RAS(ON) G12D-selective “tri-complex” inhibitor that locks mutant KRAS to cyclophilin A. In the Phase 1 RMC-9805-001 study (NCT06040541), 18 heavily pre-treated NSCLC patients with KRAS G12D…
NCT06040541 - Trial result
Non-small cell lung cancer
MK-1084 (KRAS G12C inhibitor) + pembrolizumab drives 74% ORR and 25-month PFS in first-line metastatic NSCLC
MK-1084 is an oral, next-gen covalent inhibitor that locks KRAS G12C in its inactive GDP form. In the phase 1 KANDLELIT-001 trial (NCT05067283), 21 previously treated NSCLC showed a 38% ORR and mPFS of 8 months with…
NCT05067283 - Trial result
Non-small cell lung cancer
Atezolizumab (PD-L1 mAb) Halves 5-Year Recurrence & Mortality Risk in PD-L1-High Resected NSCLC
Atezolizumab is a monoclonal antibody that targets PD-L1. In the open-label phase III IMpower010 trial (NCT02486718), 1,005 patients with completely resected stage IB–IIIA NSCLC were randomized to receive…
NCT02486718 - Trial result
Non-small cell lung cancer
Larotrectinib Delivers 69% ORR and 22-mo PFS in TRK-Fusion Lung Cancer
Larotrectinib, a highly selective CNS-penetrant TRK inhibitor, was evaluated in two Phase 1/2 trials (NCT02122913, NCT02576431) involving 32 patients with advanced TRK-fusion lung cancer—59% had ≥2 prior therapies…
NCT02122913 - Trial result
Non-small cell lung cancer
Alectinib + Bevacizumab: A Dual-Targeted Strike but Cautionary Safety Against ALK-Rearranged NSCLC
This phase 2 trial (NCT03779191) with 41 patients combines alectinib with bevacizumab in advanced ALK-positive non-small cell lung cancer (NSCLC). The combination achieved a 12-month PFS rate of 97.1% (95% CI…
NCT03779191 - Trial result
Non-small cell lung cancer
Atezolizumab (anti–PD-L1) Combo in Non-Sq NSCLC: PFS Benefit Falls Short of Significance
The IMpower151 trial (NCT04194203) combined atezolizumab plus bevacizumab and chemotherapy for first-line metastatic non-squamous NSCLC for 305 patients in China. Patients in the ABCPem/Pac arm (atezolizumab,…
NCT04194203 - Trial result
Non-small cell lung cancer
BAY 2927088 Achieves ~59% ORR in Advanced HER2-Mutant NSCLC
BAY 2927088 is a potent, orally available, HER2 (ERBB2) reversible tyrosine kinase inhibitor (TKI). In the SOHO-01 Phase I/II trial (NCT05099172), patients with advanced NSCLC with HER2-activating mutations received…
NCT05099172 - Trial result
Non-small cell lung cancer
Zipalertinib Shows Sustained EGFR Exon 20 Inhibition, Yielding similar ORR to SOC in Pre-Treated NSCLC, but Better Tolerability.
Zipalertinib (zipa, CLN-081, TAS6417) is a novel EGFR TKI designed for NSCLC patients with EGFR exon 20 insertion (ex20ins) who progressed on platinum-based chemotherapy. In the phase 2b REZILIENT1 study of 176…
- Trial result
Non-small cell lung cancer
Afatinib Shines Against Chemo in Uncommon EGFR Mutant NSCLC in Japan
In this phase 3 trial in Japan (n=109, median follow‐up 33.6 months), EGFR Mutant NSCLC patients treated with afatinib had a higher median progression-free survival of 10.8 months compared to SoC platinum‐pemetrexed…
- Trial result
Non-small cell lung cancer
Sacituzumab Tirumotecan (TROP2 ADC) Delivers a 35.7% ORR in Uncommon EGFR-Mutated NSCLC
In a phase 2 study of 42 advanced NSCLC patients with uncommon EGFR mutations, sac-TMT achieved an objective response rate of 35.7%, a disease control rate of 85.7%, and a median progression-free survival of 9.5…
- New trial
Non-small cell lung cancer
Phase II Trial of VEGFA-Targeted BNT327 with Docetaxel in Second-line Stage IV NSCLC
BioNTech SE is conducting a Phase II, multisite (Houston recruiting now), open-label, single-arm study evaluating the safety and efficacy of BNT327—a VEGFA-directed monoclonal antibody—in combination with docetaxel,…
NCT06841055 - New trial
Non-small cell lung cancer
Phase 2 Trial in Stage III NSCLC: Targeting DNA Repair with TRC102
This NCI-sponsored trial is evaluating TRC102 (a DNA repair inhibitor) in combination with standard pemetrexed-platinum therapy, radiation, and subsequent durvalumab in patients with non-squamous NSCLC, aiming to…
NCT05198830 - Trial result
Non-small cell lung cancer
Cemiplimab Boosts Survival in NSCLC Patients with Brain Metastases
In this exploratory subgroup analysis of the EMPOWER-Lung 1 study, first-line cemiplimab monotherapy in patients with advanced NSCLC and PD-L1 ≥50% with brain metastases (following radiotherapy) yielded a median…
- Trial result
Non-small cell lung cancer
Alectinib Plus Bevacizumab Yields Impressive 12-Month PFS and 100% ORR in ALK+ NSCLC
In the phase 2 ALEK-B trial, combining alectinib (600 mg BID) with bevacizumab (15 mg/kg) in 41 advanced ALK-rearranged NSCLC patients, including those with brain metastases, resulted in a 97.1% 12-month…
- Trial result
Non-small cell lung cancer
IMpower151 in Metastatic NSqNSCLC: Atezolizumab Combo Falls Short on Primary Endpoint
In this randomized double-blind phase 3 trial conducted in China with 305 chemotherapy-naive metastatic non-squamous NSCLC patients—53% of whom had EGFR+ tumors—the combination of atezolizumab, bevacizumab,…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.